LOPRESOR

This brand name is authorized in Australia, Canada, Israel, Italy, Japan, Mexico, South Africa, Spain.

Active ingredients

The drug LOPRESOR contains one active pharmaceutical ingredient (API):

1	Metoprolol UNII W5S57Y3A5L - METOPROLOL TARTRATE
	Metoprolol is a cardioselective beta-adrenergic blocking agent. It has a relatively greater blocking effect on beta1-receptors (ie those mediating adrenergic stimulation of heart rate and contractility and release of free fatty acids from fat stores) than on beta2-receptors, which are chiefly involved in broncho and vasodilation.
	Read more about Metoprolol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LOPRESOR Tablet, Solution for injection	MPI, EU: SmPC	Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AB02	Metoprolol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AB Beta blocking agents, selective
Discover more medicines within C07AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1324Q, 1325R
CA	Health Products and Food Branch	00534560, 00658855
ES	Centro de información online de medicamentos de la AEMPS	54503
IL	מִשְׂרַד הַבְּרִיאוּת	556
IT	Agenzia del Farmaco	023610013, 023610025
JP	医薬品医療機器総合機構	2149010F1033, 2149010F2072, 2149010G1055
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	87525
ZA	Health Products Regulatory Authority	H/5.2/72, R/5.2/171, X/5.2/95